China-based Ascletis Pharma Inc (HKEX code: 1672) has received approval from the National Medical Products Administration (NMPA) for its all-oral Hepatitis C virus (HCV) treatment, for marketing in China, it was reported on Thursday.
The all-oral HCV treatment is Ravidasvir (Asclevir) in combination with Danoprevir (Ganovo).
The company's phase II/III clinical trial has indicated that the treatment regimen showed a 99% cure rate with a short treatment duration of 12 weeks in genotype one patients, and in patients with baseline NS5A resistance mutations, the treatment Regimen indicated a cure rate of 100% (SVR12). National Science and Technology Major Project has chosen both Ravidasvir and Danoprevir for 'Innovative Drug Development' programs. Presidio Pharmaceuticals Inc, a clinical stage pharmaceutical company, licensed Ravidasvir.
BioArctic and Eisai secure Chinese acceptance for subcutaneous Leqembi filing
Oculis secures FDA Breakthrough Therapy Designation for Privosegtor in optic neuritis
Nanjing Delova Biotech reports positive Phase 3 trial results for QP-6211 for postoperative pain
MetaVia reports positive results from Phase 1 clinical trial in obesity
Halozyme licenses ENHANZE to Skye Bioscience for nimacimab obesity programme
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Insilico Medicine signs multi-year research and development collaboration with Servier
WuXi Biologics achieves ISO 20400 Sustainable Procurement certification
ChemPartner updates its visual identity and digital experience
Delcath publishes Phase 3 FOCUS subgroup data supporting HEPZATO in metastatic uveal melanoma
Axsome Therapeutics secures FDA priority review for AXS-05 in Alzheimer's disease agitation